~~<i id='FACEF2485A'><strike id='FACEF2485A'><tt id='FACEF2485A'><pre id='FACEF2485A'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-10-06 13:01:25 Page View：51

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Case highlights the risks of experimental stem cell therapy
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

explore

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Medicare says breakthrough device reimbursement rule to come by summer

AfederalrulethatcouldmakeMedicarereimbursementforbreakthroughdeviceseasierisslatedforearlysummer.Ado

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Case highlights the risks of experimental stem cell therapy

Neurons(red)andastrocytes(green)derivedfromhumanneuralstemcellsgrowinginculture.StevenPollard/Wellco